Paul Rutkowski, DO
Internal Medicine · Dupont, PANPI 1003078254
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $191,638 of the $193,734 with a category attached, or 98.9%. CSL Plasma Inc. accounts for 81.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $86,555 and has fallen 99.4% since, to $550 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $682.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$157K
- CSL Behring$35K
- Novo Nordisk$437
- AstraZeneca$426
- Radius Health, Inc.$203
- Medtronic$171
- plus $860 from 14 others
What the payments were for
- Consulting fees$191,63899%
- Food & beverage$2,0971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 137 | $156,875 |
| CSL Behring | 32 | $34,763 |
| Novo Nordisk | 19 | $437 |
| AstraZeneca | 25 | $426 |
| Radius Health, Inc. | 20 | $203 |
| Medtronic | 1 | $171 |
| Lilly USA, LLC | 10 | $168 |
| Boehringer Ingelheim | 6 | $116 |
| Avanir Pharmaceuticals, Inc. | 6 | $99 |
| Johnson & Johnson | 6 | $80 |
| Bayer | 4 | $64 |
| Abbott | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| GSK | 3 | $50 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Amgen | 2 | $29 |
| Biotronik NRO, Inc. | 1 | $28 |
| Exact Sciences | 1 | $21 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$171
- RYBELSUS$126
How this compares
$193,734 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $96,069 |
| XareltoRivaroxaban | 41 | $44,583 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $31,989 |
| JardianceEmpagliflozin | 43 | $26,526 |
| JanuviaSitagliptin Phosphate | 40 | $19,217 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $18,092 |
| OzempicSemaglutide | 11 | $17,236 |
| FarxigaDapagliflozin Propanediol | 41 | $14,892 |
| OxycontinOxycodone Hcl | 11 | $10,199 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $6,167 |
| Atorvastatin Calcium | 633 | $6,128 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,878 |
| DuleraMometasone/Formoterol | 18 | $5,691 |
| Gabapentin | 220 | $3,978 |
| Levothyroxine Sodium | 427 | $3,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $50 | $55,96093 claims |
| Johnson & JohnsonXarelto | $80 | $44,58341 claims |
| Boehringer IngelheimJardiance | $116 | $26,52643 claims |
| Novo NordiskOzempic | $437 | $17,23611 claims |
| AstraZenecaFarxiga | $426 | $14,89241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Dupont
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.